ANIP · Ani Pharmaceuticals Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted non-GAAP diluted earnings per share non-GAAP | $2.05 | first quarter of 2026 | — |
|
|
|||
| Brands net revenues | $12.3M | the first quarter of 2026 | -51.0% |
|
|
|||
| Cortrophin Gel net revenues | $75.1M | the first quarter of 2026 | +42.1% |
|
|
|||
| Generics net revenues | $105.4M | the first quarter of 2026 | +6.8% |
|
|
|||
| ILUVIEN and YUTIQ net revenues | $19.26M | FY2026 Q1 | +19.5% |
|
|
|||
| ILUVIEN net revenues | $19.3M | the first quarter of 2026 | +19.8% |
|
|
|||
| Purified Cortrophin Gel net revenues | $75.12M | FY2026 Q1 | +42.1% |
|
|
|||
| Adjusted non-GAAP EBITDA non-GAAP | $229.8M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIP
this stock
Ani Pharmaceuticals Inc
|
$1.77B | -0.5% | +2.5% | 19.9 | 14.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.06B | +10.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.54B | +2.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.07B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIP | -4.1% | -5.1% | -4.2% | -5.1% | -0.5% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.5% | -5.7% | -10.6% | -4.0% | -8.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.